Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSCT for Hurler, Maroteaux-Lamy, and Mannosidosis
NCT00176917Phase 2Completed
- Sponsor
- Masonic Cancer Center
- Start
- May 1999
- Primary completion
- May 2008
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hematopoietic stem cells in mucopolysaccharidosis type I, mucopolysaccharidosis type VI, alpha-mannosidosis and 1 more, sponsored by Masonic Cancer Center. Primary endpoint: Mean Percentage of Donor Cells in Study Population at 1 year. Started May 1999; status: completed.
02
Drugs
hematopoietic stem cells
03
Conditions
mucopolysaccharidosis type Imucopolysaccharidosis type VIalpha-mannosidosisMucolipidosis II
Beyond the preview
Go deeper on NCT00176917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00176917.